新生血管性年龄相关性黄斑变性患者接受雷珠单抗治疗2个月后房水中多种细胞因子浓度的变化
这项前瞻性研究纳入48例未治疗的新生血管性AMD患眼,每月连续注射雷珠单抗3次,于第1次和第3次(2个月后)注射前采集房水,并与80例无视网膜疾病的白内障眼对照。结果显示除MMP-9显著升高外,其余多种炎症细胞因子浓度均显著下降。
要点
- 连续2次每月雷珠单抗注射后,房水中CXCL1、IP-10、CXCL12、CXCL13、MCP-1、CCL11、IL-6、IL-10浓度均显著下降(均p<0.0001)。
- MMP-9浓度从0.92 pg/mL升至1.5 pg/mL(p=0.0216),是唯一显著升高的因子。
- 研究为前瞻性设计,48例新生血管性AMD患眼,对照为80例无视网膜疾病的白内障眼。
核心结论
- 连续2次每月抗VEGF注射后,AMD患眼房水中炎症细胞因子水平被强烈抑制,而MMP-9水平升高。
研究设计与样本
- 前瞻性研究,纳入2010年11月至2012年8月在日本社区医疗组织东京新宿医疗中心接受每月连续3次雷珠单抗注射的48例未治疗新生血管性AMD患眼(48例患者)。
- 于第1次和第3次(2个月后)注射前采集约0.2 mL房水,对照为80例无视网膜疾病的白内障眼。
- 采用多重细胞因子检测分析CXCL1、IP-10、CXCL12、CXCL13、MCP-1、CCL11、IL-6、IL-10和MMP-9。
主要发现
- AMD患者平均年龄73岁,对照75岁;男性分别为31例(65%)和37例(46%)。
- 27眼(56%)发现息肉状脉络膜血管病变。
- 第1次与第3次注射前房水细胞因子平均浓度(pg/mL):CXCL1 8.4 vs 3.3;IP-10 110 vs 55;CXCL12 480 vs 240;CXCL13 9.2 vs 2.6;MCP-1 620 vs 220;CCL11 7.1 vs 2.8;IL-6 5.9 vs 1.6;IL-10 0.15 vs 0.015(均p<0.0001)。
- MMP-9浓度从0.92 pg/mL升至1.5 pg/mL(p=0.0216)。
- 除MMP-9显著升高外,所有其他细胞因子浓度在连续2次雷珠单抗注射后均显著下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012. We collected ~0.2 mL aqueous humour before the first and third (2 months later) injections. Controls were 80 eyes with cataracts without retinal disease. The cytokines C-X-C motif chemokine ligand 1 (CXCL1), interferon-γ-induced protein 10 (IP-10), C-X-C motif chemokine ligand 12 (CXCL12), C-X-C motif chemokine ligand 13 (CXCL13), monocyte chemoattractant protein 1 (MCP-1), CCL11, C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), interleukin-10 (IL-10) and matrix metalloproteinase 9 (MMP-9) were analysed using multiplex cytokine assays. RESULTS: Mean ages of the patients with AMD and controls were 73 and 75 years, respectively, and 31 (65%) and 37 (46%) subjects were men, respectively. Polypoidal choroidal vasculopathy was found in 27 eyes (56%). Mean concentrations of cytokines in aqueous humour in patients with neovascular AMD before the first and third ranibizumab injections were as follows (in pg/mL): CXCL1, 8.4 and 3.3; IP-10, 110 and 55; CXCL12, 480 and 240; CXCL13, 9.2 and 2.6; MCP-1, 620 and 220; CCL11, 7.1 and 2.8; IL-6, 5.9 and 1.6; IL-10, 0.15 and 0.015 (all p<0.0001), and MMP-9, 0.92 and 1.5 (p=0.0216), respectively. Concentrations of all cytokines decreased significantly after two consecutive ranibizumab injections, except for MMP-9, which increased significantly. CONCLUSIONS: After two monthly consecutive antivascular endothelial growth factor injections, inflammatory cytokine levels in the aqueous humour of the eyes with AMD were strongly suppressed, while MMP-9 levels increased.
引用
- Sakamoto S, Takahashi H, Tan X, et al. Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol. 2017. PMID: 28765149. doi:10.1136/bjophthalmol-2017-310284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。